ELECTROCONVULSIVE THERAPY IN PARKINSON'S DISEASE

ELEXANDRA APARECIDA SIMÕES, IGOR YOSHIMITSU BAMBIL UJIIE, JÉSSIKA CRISTINA CESCO, MAISA MAIA ESTEVÃO, EMERSON HENKLAIN FERRUZZI

Resumo


Introduction: Parkinson's disease (PD) is characterized by motor symptoms (bradykinesia, resting tremor,
rigidity, gait disturbances) and non-motor symptoms1. In this group, depression and psychosis are the
main neuropsychiatric disorders, with an important role in reduced quality of life and disability of
patients4,5. The Electroconvulsive Therapy (ECT) is a therapeutic approach adopted in Psychiatry, with
increasing advances in treatment option for this group of patients. Objective: Present the ECT as a
treatment option for depression and / or psychosis associated with PD. Materials and Methods: This
research consists of a literature review on theoretical frameworks, including books and articles published
in English and Portuguese. The databases were "Medline" and "PubMed". Results: Studies show
improvement in both depression and psychosis, for example in the study of Calderón-Fajardo et al
pointing 27 patients (14 with depression, 12 with depression and psychosis and a patient with psychosis)
treated with electroconvulsive therapy showed improvements in Brief Psychiatric Rating Scale and
Hamilton Depression Rating Scale. The Unified Parkinson's scale Disease Rating Scale part III (UPDRS-III)
there is 30% improvement in UPDRS-IV and there are down 39% proving the safety and effectiveness of
treatment2. There is a report reduction by about 20 points on UPDRS-III one week after the procedure.
Discussion and Conclusion: Antidepressants and antipsychotic drugs are regarded as first-line treatment
of depression and psychosis associated with SD7.8. However, ECT was developed in 1938, has gained
notoriety for effective results in the treatment of depression and / or psychosis associated with PD
refractory to drug treatment, promoting decrease of motor and non-motor manifestations safely5.6,8.
There are also positive reports of ECT in the treatment of anxiety, catotonia, apathy, hallucinations and
obsessive-compulsive disorder associated with Parkinson's4. The mechanism of action is still unknown,
but the most accepted hypothesis is to increase in response to the post-synaptic dopamine regulation of
dopamine receptors in the striatum of the hypothalamus and increased levels of levodopa by disorder of
blood-brain barrier, increases serotonin neurotransmission and promotes the activation of
mesocorticolimbic pathways, leading an increase of the anterior cingulate cortex and hippocampal
metabolism, these effects may explain the mechanisms antidepressants and antipsychotics2,7,8. In animal
models it was observed hyperplasia of cells in the dentate gyrus suggesting that the ECT encourages
regeneration of neurons in the hippocampus4. The ECT procedure requires that the patient is sedated
with general anesthesia, electrodes are placed in particular to the head and by means of electrical current controlled regions causes a seizure in the brain, with a remarkable safety procedure. Are usually needed
six to twelve sessions to symptoms improve and stabilize4.6. Side effects are well tolerated and the most
common are headache, epigastric pain, myalgia and recent memory disorders6. Thus, ECT is an effective
procedure in the treatment of depression and psychosis refractory to drug treatment and should be used
as a therapeutic option in order to improve the patient's quality of life.



Texto completo:

PDF

Referências


Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Medicina Interna de Harrison. 18ª

ed. Porto Alegre: AMGH, 2013.

Calderón-Fajardo H, et al. Electroconvulsive therapy in Parkinson’s disease. Arq Neuropsiquiatr. 2015:

-5.

Zahodne LB, Fernandez HH. A review of the pathophisiology and treatment of psychosis in Parkinson’s

disease. Drugs Aging. 2008; 25(8): 665 - 682.

Nishioka K, et al. Quantitative evaluation of electroconvulsive therapy for Parkinson’s disease with

refractory psychiatric symptoms. J Neural Transm. 2014; 121(11): 1405-10.

National Institute of Mental Health. Depression and Parkinson’s disease. 2011. Disponível em:

.

Acesso em: 15 set 2015.

National Institute of Mental Health. Brain stimulation therapies. Disponível em:

. Acesso em: 15 set 2015.

Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a

review. Drugs Aging. 2008; 25(8): 665-82. Disponível em:

. Acesso em: 15 set 2015.

Fregni F, Simon DK, Wu A, Pascual-Leone A. Non-invasive brain stimulation for Parkinson’s disease: a

systematic review and meta-analysis of the literature. Journal of neurology, neurosurgery, adn psychiatry.

; 76(12): 1614-23. Disponível

em:. Acesso em: 15 set


Apontamentos

  • Não há apontamentos.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.